1Chan D C, Fass D, Berger J M, et al. Core structure of gp41 from the HIV envelope glycoprotein[J]. Cell, 1997,B9: 263.
2Jiang S, Lin K, Zhang L, et al. A screening assay for antiviral compounds targeted to the HIV-1 gp41 core structure using a conformation-specific monoclonal antibody[J]. J Virol Methods, 1999,80 : 85.
3Debnath A K, Lin K, Jiang S. Structure-based identification of small molecule antiviraI compounds targeted to the gp41 core structure of the human immunodeficiency virus type 1 [J]. J Med Chem, 1999,42:3203.
4Eckert D M, Malashkevich V N, Hong I. H, et al. Inhibiting HIV-1 Entry: Discovery of D-Peptide Inhibitors that Target the gp41 Coiled-Coil Pocket[J]. Cell, 1999,99 : 103.
5Daria J, Hazuda P F, Wjtmer M,et al.Inhihitors of strand transfer that prevent integration and inhibit HIV-integase catalytic domain complexed with an inhibitorfa platform for antiviral drug design [J]. Proc Natl Acad Sci USA, 1999,96 : 13040.
6King P J, Ma G, Miao W, et al. Structure-activity relationships; analogues of the dicaffeoylquenic and dicaffeoyltartaric acids as potent inhibitors of human immunodeficiency virus type-I integrase and replication [J]. J Med Chem, 1999,42,497.
